Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2015 ASCO Annual Meeting

29 May - 2 Jun 2015

McCormick Place, Chicago, United States of America

New trial will link targeted cancer drugs to gene abnormalities

New trial will link targeted cancer drugs to gene abnormalities

Oral cancer therapy combination prevents progression of advanced melanoma for over a year

Oral cancer therapy combination prevents progression of advanced melanoma for over a year

Study demonstrates survival benefits of immunotherapy MPDL3280A for lung cancer patients compared with chemotherapy

Study demonstrates survival benefits of immunotherapy MPDL3280A for lung cancer patients compared with chemotherapy

$European Commission grants marketing authorization for lenvatinib in advanced RAI-refractory differentiated thyroid cancer$

European Commission grants marketing authorization for lenvatinib in advanced RAI-refractory differentiated...

ASCO 2015: Pembrolizumab may be promising treatment for urothelial cancer

ASCO 2015: Pembrolizumab may be promising treatment for urothelial cancer

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: Improved care has extended the lifespan of childhood cancer survivors since the 1970s

ASCO 2015: Improved care has extended the lifespan of childhood cancer survivors since the 1970s

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: Preventive neck lymph node surgery improves early oral cancer survival

ASCO 2015: Preventive neck lymph node surgery improves early oral cancer survival

ASCO 2015: Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases

ASCO 2015: Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain...

ASCO 2015: Extensive lymph node surgery may not be necessary for some patients with melanoma

ASCO 2015: Extensive lymph node surgery may not be necessary for some patients with melanoma

ASCO 2015: First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

ASCO 2015: First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

ASCO 2015: Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

ASCO 2015: Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: First effective adjuvant chemotherapy for high-risk, localised prostate cancer

ASCO 2015: First effective adjuvant chemotherapy for high-risk, localised prostate cancer

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Nivolumab extends survival for patients with the most common lung cancer

ASCO 2015: Nivolumab extends survival for patients with the most common lung cancer

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

ASCO 2015: Genomic marker predicts anti-PD-1 response in several cancers

ASCO 2015: Genomic marker predicts anti-PD-1 response in several cancers

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Augmenting standard therapies increases cure rates for high-risk wilms tumour

ASCO 2015: Augmenting standard therapies increases cure rates for high-risk wilms tumour

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

ASCO 2015: Adding elotuzumab significantly reduces risk of progression for relapsed multiple myeloma

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

ASCO 2015: Simple oral vitamin reduces risk of common, non-melanoma skin cancers

More from ecancer